Karolina Poplawska-Domaszewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karolina Poplawska-Domaszewicz has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Kallol Ray Chaudhuri
King’s College Hospital
3 shared publications - Cristian Falup-Pecurariu
Department of Neurology Transilvania University Brasov Romania
2 shared publications - Daniele Urso
From the Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari “Aldo Moro”, “Pia Fondazione Cardinale G. Panico”, Tricase, Lecce, Italy
2 shared publications - Lucia Batzu
King's College London, UK
2 shared publications - Alessia Giugno
Institute of Neurology, Department of Medical and Surgical Sciences Magna Græcia University Catanzaro Italy
1 shared publication - Alexander Storch
Department of Neurology, Rostock University Medical Center, Rostock, Germany
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in Movement Disorders
Apathy in Lewy Body Disorders: A Position Paper
Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains underrecognized and undertreated. A Working Group of the International Parkinson and Movement Disorder Society's Non‐Motor Symptoms Study Group conducted a comprehensive review of the literature and developed a position paper through iterative expert discussion and critical appraisal of available data. This review aims to provide a structured, expert‐informed synthesis of the current evidence on the clinical features, neurobiology, assessment, and management of apathy in LBDs and to define priorities for future research and clinical trials. Apathy in LBDs is a multidimensional syndrome encompassing reward insensitivity, negative affect, executive dysfunction, and auto‐activation deficits. Converging evidence implicates dysfunction within distributed frontal‐striatal‐limbic networks and multi‐neurotransmitter systems, including dopaminergic, serotonergic, noradrenergic, and cholinergic pathways. Although several pharmacological and nonpharmacological interventions have been explored, few randomized controlled trials have specifically targeted apathy, and no treatment can currently be considered definitively efficacious. Methodological heterogeneity, inadequate phenotyping, and inconsistent outcome measures have limited therapeutic progress. Apathy should be recognized as a primary clinical and research priority in LBDs. Future adequately powered, mechanistically informed trials using standardized diagnostic criteria and validated outcome measures are urgently needed to advance treatment development. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 13 August 2026
- Published by Wiley in Movement Disorders
Open AccessApathy in Lewy Body Disorders: A Position Paper
Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains underrecognized and undertreated. A Working Group of the International Parkinson and Movement Disorder Society's Non‐Motor Symptoms Study Group conducted a comprehensive review of the literature and developed a position paper through iterative expert discussion and critical appraisal of available data. This review aims to provide a structured, expert‐informed synthesis of the current evidence on the clinical features, neurobiology, assessment, and management of apathy in LBDs and to define priorities for future research and clinical trials. Apathy in LBDs is a multidimensional syndrome encompassing reward insensitivity, negative affect, executive dysfunction, and auto‐activation deficits. Converging evidence implicates dysfunction within distributed frontal‐striatal‐limbic networks and multi‐neurotransmitter systems, including dopaminergic, serotonergic, noradrenergic, and cholinergic pathways. Although several pharmacological and nonpharmacological interventions have been explored, few randomized controlled trials have specifically targeted apathy, and no treatment can currently be considered definitively efficacious. Methodological heterogeneity, inadequate phenotyping, and inconsistent outcome measures have limited therapeutic progress. Apathy should be recognized as a primary clinical and research priority in LBDs. Future adequately powered, mechanistically informed trials using standardized diagnostic criteria and validated outcome measures are urgently needed to advance treatment development. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 20 May 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (5) , 939-946
Handgrip strength and relationship with non-motor symptoms in Parkinson's disease
Background: Muscle weakness, particularly reduced handgrip strength (HGS), is a prominent clinical feature in Parkinson's disease (PD). While the relationship between motor symptoms and muscle strength has been extensively studied, the connection between HGS and non-motor symptoms (NMS) remains less explored. Objective: This study investigates the relationship between HGS and NMS in PD patients, hypothesizing that higher burden of NMS is associated with a reduced HGS. Methods: Fifty consecutive PD patients were enrolled and underwent comprehensive neurological and neuropsychological evaluations, 3T MRI scans, routine laboratory tests, and 123 I-Ioflupane SPECT imaging. HGS was measured using a DynEx hand dynamometer, and NMS were assessed using the Non-Motor Symptoms Scale (NMSS). Cognitive function was evaluated with a battery of 18 psychometric tests, and quality of life was assessed using the Parkinson's Disease Questionnaire-8 (PDQ-8). Results: Reduced HGS was observed in the majority of PD patients and was significantly correlated with higher NMSS scores, particularly in mood and cognitive domains. Lower HGS was also linked to poorer quality of life. In linear regression models, NMSS remained a significant predictor of HGS even when controlling for age, sex, and Mini-Mental State Examination scores. Conclusions: Our findings suggest that HGS could serve as a valuable biomarker for non-motor symptoms, including depression and cognitive dysfunction, in PD patients. This study underscores the importance of integrating HGS measurements into clinical practice to identify muscle weakness and cognitive impairment, guiding more targeted interventions to improve patient outcomes.
- 20 May 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (5) , 939-946
Open AccessHandgrip strength and relationship with non-motor symptoms in Parkinson's disease
Background: Muscle weakness, particularly reduced handgrip strength (HGS), is a prominent clinical feature in Parkinson's disease (PD). While the relationship between motor symptoms and muscle strength has been extensively studied, the connection between HGS and non-motor symptoms (NMS) remains less explored. Objective: This study investigates the relationship between HGS and NMS in PD patients, hypothesizing that higher burden of NMS is associated with a reduced HGS. Methods: Fifty consecutive PD patients were enrolled and underwent comprehensive neurological and neuropsychological evaluations, 3T MRI scans, routine laboratory tests, and 123 I-Ioflupane SPECT imaging. HGS was measured using a DynEx hand dynamometer, and NMS were assessed using the Non-Motor Symptoms Scale (NMSS). Cognitive function was evaluated with a battery of 18 psychometric tests, and quality of life was assessed using the Parkinson's Disease Questionnaire-8 (PDQ-8). Results: Reduced HGS was observed in the majority of PD patients and was significantly correlated with higher NMSS scores, particularly in mood and cognitive domains. Lower HGS was also linked to poorer quality of life. In linear regression models, NMSS remained a significant predictor of HGS even when controlling for age, sex, and Mini-Mental State Examination scores. Conclusions: Our findings suggest that HGS could serve as a valuable biomarker for non-motor symptoms, including depression and cognitive dysfunction, in PD patients. This study underscores the importance of integrating HGS measurements into clinical practice to identify muscle weakness and cognitive impairment, guiding more targeted interventions to improve patient outcomes.
- Open Access
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 1-16
Non-Motor Fluctuations in Parkinson’s Disease: Underdiagnosed Yet Important
Non-motor fluctuations (NMFs) in Parkinson’s disease (PD) significantly affect patients’ well-being. Despite being identified over two decades ago, NMFs remain largely underrecognized, undertreated, and poorly understood. While they are often temporally associated with motor fluctuations (MFs) and can share common risk factors and pathophysiologic mechanisms, NMFs and MFs are currently considered distinct entities. The prevalence and severity of NMFs, often categorized into neuropsychiatric, sensory, and autonomic subtypes, vary significantly across studies due to the heterogeneous PD populations screened and the diverse evaluation tools applied. The consistent negative impact of NMFs on PD patients’ quality of life underscores the importance of further investigations via focused and controlled studies, validated assessment instruments and novel digital technologies. High-quality research is essential to illuminate the complex pathophysiology and clinical nuances of NMFs, ultimately enhancing clinicians’ diagnostic and treatment options in routine clinical practice.
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 1-16
Open AccessNon-Motor Fluctuations in Parkinson’s Disease: Underdiagnosed Yet Important
Non-motor fluctuations (NMFs) in Parkinson’s disease (PD) significantly affect patients’ well-being. Despite being identified over two decades ago, NMFs remain largely underrecognized, undertreated, and poorly understood. While they are often temporally associated with motor fluctuations (MFs) and can share common risk factors and pathophysiologic mechanisms, NMFs and MFs are currently considered distinct entities. The prevalence and severity of NMFs, often categorized into neuropsychiatric, sensory, and autonomic subtypes, vary significantly across studies due to the heterogeneous PD populations screened and the diverse evaluation tools applied. The consistent negative impact of NMFs on PD patients’ quality of life underscores the importance of further investigations via focused and controlled studies, validated assessment instruments and novel digital technologies. High-quality research is essential to illuminate the complex pathophysiology and clinical nuances of NMFs, ultimately enhancing clinicians’ diagnostic and treatment options in routine clinical practice.
- Open Access
- 11 April 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 131 (12) , 1495-1509
Parkinson's disease and vitamins: a focus on vitamin B12
Parkinson’s disease (PD) has been linked to a vast array of vitamins among which vitamin B12 (Vit B12) is the most relevant and often investigated specially in the context of intrajejunal levodopa infusion therapy. Vit B12 deficiency, itself, has been reported to cause acute parkinsonism. Nevertheless, concrete mechanisms through which B12 deficiency interacts with PD in terms of pathophysiology, clinical manifestation and progression remains unclear. Recent studies have suggested that Vit B12 deficiency along with the induced hyperhomocysteinemia are correlated with specific PD phenotypes characterized with early postural instability and falls and more rapid motor progression, cognitive impairment, visual hallucinations and autonomic dysfunction. Specific clinical features such as polyneuropathy have also been linked to Vit B12 deficiency specifically in context of intrajejunal levodopa therapy. In this review, we explore the link between Vit B12 and PD in terms of physiopathology regarding dysfunctional neural pathways, neuropathological processes as well as reviewing the major clinical traits of Vit B12 deficiency in PD and Levodopa-mediated neuropathy. Finally, we provide an overview of the therapeutic effect of Vit B12 supplementation in PD and posit a practical guideline for Vit B12 testing and supplementation.
- 11 April 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 131 (12) , 1495-1509
Open AccessParkinson's disease and vitamins: a focus on vitamin B12
Parkinson’s disease (PD) has been linked to a vast array of vitamins among which vitamin B12 (Vit B12) is the most relevant and often investigated specially in the context of intrajejunal levodopa infusion therapy. Vit B12 deficiency, itself, has been reported to cause acute parkinsonism. Nevertheless, concrete mechanisms through which B12 deficiency interacts with PD in terms of pathophysiology, clinical manifestation and progression remains unclear. Recent studies have suggested that Vit B12 deficiency along with the induced hyperhomocysteinemia are correlated with specific PD phenotypes characterized with early postural instability and falls and more rapid motor progression, cognitive impairment, visual hallucinations and autonomic dysfunction. Specific clinical features such as polyneuropathy have also been linked to Vit B12 deficiency specifically in context of intrajejunal levodopa therapy. In this review, we explore the link between Vit B12 and PD in terms of physiopathology regarding dysfunctional neural pathways, neuropathological processes as well as reviewing the major clinical traits of Vit B12 deficiency in PD and Levodopa-mediated neuropathy. Finally, we provide an overview of the therapeutic effect of Vit B12 supplementation in PD and posit a practical guideline for Vit B12 testing and supplementation.
- Open Access
- 7 February 2019
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 88 (1) , 12-20
LC-MS/MS based targeted metabolomics method for analysis of serum and cerebrospinal fluid
Introduction. Recent instrumentation and software advancement enabled to develop new, high‑throughput targeted metabolomics methods for in‑depth exploration of metabolome in a quantitative manner.Material and Methods. The presented targeted metabolomics approach allows to analyze both of serum and CSF in the same way, with identical sample preparation procedures. The analyses were carried out using high‑performance liquid chromatography system coupled to triple quadrupole tandem mass spectrometer with electrospray ion source (LC‑ESI‑QqQ‑MS/MS). Results. The applied targeted metabolomics approach enabled to determine a wide panel of metabolites from different chemical classes of compounds including: acylcarnitines, amino acids and biogenic amines, glycerophospholipids, sphingolipids and sum of hexoses. Finally, 148 metabolites in serum and 57 in cerebrospinal fluid were determined.Conclusions. Here we presented the results of successful implementation of the method of analysis of low‑molecular weight compounds in human serum and CSF using targeted metabolomics. The evaluation of selected groups of metabolites resulted in obtaining the mean concentrations of panel of metabolites in serum and CSF, which gives a valuable information about the metabolome of these matrices.
- 7 February 2019
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 88 (1) , 12-20
Open AccessLC-MS/MS based targeted metabolomics method for analysis of serum and cerebrospinal fluid
Introduction. Recent instrumentation and software advancement enabled to develop new, high‑throughput targeted metabolomics methods for in‑depth exploration of metabolome in a quantitative manner.Material and Methods. The presented targeted metabolomics approach allows to analyze both of serum and CSF in the same way, with identical sample preparation procedures. The analyses were carried out using high‑performance liquid chromatography system coupled to triple quadrupole tandem mass spectrometer with electrospray ion source (LC‑ESI‑QqQ‑MS/MS). Results. The applied targeted metabolomics approach enabled to determine a wide panel of metabolites from different chemical classes of compounds including: acylcarnitines, amino acids and biogenic amines, glycerophospholipids, sphingolipids and sum of hexoses. Finally, 148 metabolites in serum and 57 in cerebrospinal fluid were determined.Conclusions. Here we presented the results of successful implementation of the method of analysis of low‑molecular weight compounds in human serum and CSF using targeted metabolomics. The evaluation of selected groups of metabolites resulted in obtaining the mean concentrations of panel of metabolites in serum and CSF, which gives a valuable information about the metabolome of these matrices.